Immune checkpoint inhibitor (ICI)-based regimens are becoming a standard first-line therapy in advanced NSCLC and in neoadjuvant/adjuvant settings. Yet frontline treatment of advanced NSCLC is challenging, as programmed death-ligand 1 status must be considered in relation to specific ICI indications. In earlier stage NSCLC, clinicians must consider newer surrogate endpoints, pathologic response criteria, and the relative benefits of neoadjuvant versus adjuvant treatment. Join this engaging discussion on the use of ICIs across all stages of NSCLC.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/EFYYAQ
- Start Date: 2024-07-31 05:00:00
- End Date: 2024-07-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 114000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest